2022 International Lymphangioleiomyomatosis (LAM) Research Conference
2022年国际淋巴管平滑肌瘤病(LAM)研究会议
基本信息
- 批准号:10539078
- 负责人:
- 金额:$ 4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-10 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvisory CommitteesAppointmentAreaAttentionAwardBiologyCOVID-19COVID-19 pandemicChicagoChronicClinicClinicalClinical InvestigatorClinical ManagementClinical TrialsClinical Trials DesignCollaborationsCommunitiesComplementCongressesConsciousCountryDiffuseDisciplineDiseaseDisease remissionDissectionDyspneaEnsureEstrogensExertionFDA approvedFRAP1 geneFamilyFamily memberFemaleFoundationsFriendsFriendshipsFutureGenesGoalsGrantGuidelinesHaresHealthImageImaging TechniquesImmersionImmunotherapyIndividualInternationalInterstitial Lung DiseasesLifeLungLung diseasesLymphangiogenesisLymphangioleiomyomatosisLymphaticMetabolismMindMolecularMolecular TargetMolecular and Cellular BiologyMonitorMulticenter StudiesMutationOralPathogenesisPathway interactionsPatient-Focused OutcomesPatientsPersonsPhasePhysiciansPleural DiseasesProceduresQuality of lifeRandomizedReadinessRecurrenceResearchResearch DesignResearch PersonnelRespiratory FailureRoleScienceScientific Advances and AccomplishmentsScientistSeriesSignal TransductionSirolimusSmooth MuscleSocial DistanceSymptomsTherapeuticTherapeutic TrialsTimeTranslatingTravelTuberous SclerosisUnderrepresented MinorityUterusVaccineeWomanWorkauthoritybasecareercell growthclinical biomarkersclinical careclinical investigationclinical practicedesigndiversity and inclusiondouble-blind placebo controlled trialethnic diversityexperiencegender diversitygene productimprovedinnovationinterestmTOR Inhibitormeetingsmetabolomicsnext generationnovelnovel strategiesnovel therapeuticspatient orientedpatient safetypeer coachingpostersprogramspulmonary function declineracial diversityrecruitsingle-cell RNA sequencingsocialsuccesssymposiumsynergismtumor microenvironment
项目摘要
Project Summary
Our purpose is to: 1) Review exciting advances in single cell RNAseq estrogen/uterine signaling, immunotherapy
and metabolic processes that are relevant to LAM, 2) Provide a forum for LAM Clinic Directors to promote best
practices, refine LAM Guidelines, discuss difficult cases, and set priorities, 3) Set the stage for sustainable
scientific progress by encouraging and nurturing the early career researchers (ECRs), and 4) Enable full
immersion and integration of patients and families into all facets of the symposium to design research that
addresses their priorities. The meeting will completely occupy the Hilton Rosemont in Chicago, a conference
facility and hotel within two miles of Chicago O’Hare Airport. ECRs will be encouraged by prioritizing speaker
slots, travel and lodging reimbursement, and arranging an exclusive ECR social following the poster session.
Active engagement with peers, mentors, and patients will introduce young scientists to the joys of a career in
goal oriented, disease-focused research and help recruit and retain them to study LAM. Four half-day plenary
sessions composed of invited speakers and platform presentations from selected abstracts will form the core of
the meeting on Friday and Saturday. The basic and translational focus of the meeting will be on improved
understanding of the tumor microenvironment, and identification of molecular targets and clinically useful
biomarkers, using novel approaches that include advanced imaging, single cell RNA sequencing, metabolomics
and clues from known intersection of mTOR signaling with uterine/estrogen biology. A poster session and
discussion focused to junior investigators will be held on Friday afternoon. Clinical talks will be incorporated into
most sessions to hold the attention of an audience with diverse areas of interest and expertise. A concurrent
patient-oriented seminar series will address key issues for ~200 LAM patients and family members, culminating
in a summary of scientific sessions by the conference chairs on Sunday. A LAM Clinic Directors meeting will be
convened on Friday evening to discuss challenging cases and set priorities for the network. Each session will be
chaired by an expert and include invited speakers as well as speakers chosen from submitted abstracts, with a
focus on ECR recruitment. There has been a conscious effort to attract diverse investigators from related
disciplines who can complement the expertise of LAM investigators. Discussions facilitated by an experienced
leader/moderator will be an importantcomponent of all sessions. Outstanding ECRs will be awarded travel grants
based on merit and will begiven the opportunity to present their research in platform and poster formats. Specific
attention will be given to ensure the speaker portfolio represents gender, racial and ethnic diversity.
In summary, our goal is to provide a forum for experts to discuss the molecular and cellular basis of LAM,
review the clinical management of LAM, to present cutting edge research, integrate concepts, identify creative
and innovative research directions, and ultimately, improve the health and quality of life of patients with LAM.
项目摘要
我们的目的是:1)综述单细胞RNAseq雌激素/子宫信号转导、免疫治疗的令人振奋的进展
和与LAM相关的代谢过程,2)为LAM诊所主任提供一个论坛,以促进最佳
实践,完善LAM指导方针,讨论疑难案例,确定优先事项,3)为可持续发展奠定基础
通过鼓励和培养早期职业研究人员(ECR)实现科学进步,以及4)使充分
将患者和家属融入研讨会的方方面面,以设计
解决他们的优先事项。此次会议将彻底占据芝加哥罗斯蒙特希尔顿酒店的一场会议
设施和酒店距离芝加哥奥黑尔机场不到两英里。ECR将通过优先发言人来鼓励
老虎机,旅行和住宿报销,并在海报会议后安排独家ECR社交。
与同行、导师和患者的积极接触将向年轻科学家介绍职业生涯的乐趣
以目标为导向,以疾病为重点的研究,并帮助招募和留住他们学习LAM。四个半天的全体会议
由特邀演讲者和精选摘要的平台演示组成的会议将构成
周五和周六的会议。会议的基本和翻译重点将是改进
对肿瘤微环境的了解、分子靶点的确定及临床应用
生物标记物,使用新的方法,包括先进的成像,单细胞RNA测序,代谢组学
以及已知的mTOR信号与子宫/雌激素生物学交叉的线索。张贴会和
周五下午将举行以初级调查人员为重点的讨论。临床讲座将纳入
大多数会议都是为了吸引具有不同兴趣领域和专业知识的观众的注意力。一个并发的
以患者为中心的系列研讨会将为约200名LAM患者和家庭成员解决关键问题,最终
在周日会议主席的科学会议总结中。LAM诊所主任会议将于
周五晚上召开会议,讨论具有挑战性的案件,并为网络设定优先事项。每节课都会是
由一名专家担任主席,包括受邀演讲者以及从提交的摘要中选择的演讲者,并附有
专注于ECR招聘。有意识地努力吸引来自Related的不同调查人员
这些学科可以补充LAM调查人员的专业知识。由经验丰富的
领导/主持人将是所有会议的重要组成部分。杰出的ECR将获得旅行津贴
基于优点,并将有机会以平台和海报形式展示他们的研究。特定的
将注意确保发言者组合代表性别、种族和族裔多样性。
总而言之,我们的目标是为专家提供一个论坛,讨论LAM的分子和细胞基础,
回顾LAM的临床管理,展示前沿研究,整合概念,确定创新
和创新的研究方向,最终提高LAM患者的健康和生活质量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nishant Gupta其他文献
Nishant Gupta的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nishant Gupta', 18)}}的其他基金
Menstrual Cycle-Related Symptom Variability as a Prognostic Indicator in Lymphangioleiomyomatosis
月经周期相关症状变异性作为淋巴管平滑肌瘤病的预后指标
- 批准号:
10513485 - 财政年份:2022
- 资助金额:
$ 4万 - 项目类别:
Menstrual Cycle-Related Symptom Variability as a Prognostic Indicator in Lymphangioleiomyomatosis
月经周期相关症状变异性作为淋巴管平滑肌瘤病的预后指标
- 批准号:
10669246 - 财政年份:2022
- 资助金额:
$ 4万 - 项目类别:
Resveratrol and Sirolimus in LAM Trial (RESULT)
LAM 试验中的白藜芦醇和西罗莫司(结果)
- 批准号:
9374597 - 财政年份:2017
- 资助金额:
$ 4万 - 项目类别:
相似海外基金
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
- 批准号:
0451289 - 财政年份:2005
- 资助金额:
$ 4万 - 项目类别:
Standard Grant














{{item.name}}会员




